

《肝癌抗癌藥物治療指引》

Hepatocellular Carcinoma

First-line systemic therapy

Sorafenib (Child-Pugh Class A [category 1] or B7)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Sorafenib	400mg PO BID				1, 2

Lenvatinib (Child-Pugh Class A only)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Lenvatinib	8 or 12mg* PO QD				5

*8 mg/day for BW <60 kg; 12 mg/day for BW ≥ 60 kg

Atezolizumab + Bevacizumab (Child-Pugh Class A only)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	1	Q3W		8
Bevacizumab	15 mg/kg	1	Q3W		

Tremelimumab + Durvalumab

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Tremelimumab	300 mg	1	Single dose		14
Durvalumab	1500 mg	1	Q3W		

Durvalumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Durvalumab	1500 mg		Q4W		12

Pembrolizumab

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg		Q3W		13

Useful in Certain Circumstances

Nivolumab (If ineligible for [TKIs] or other anti-angiogenic agents) (category 2B)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg		Q2W		9

TKIs: tyrosine kinase inhibitors

Nivolumab + Ipilimumab (for TMB-H tumors)

藥品名*	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W		15
Ipilimumab	1 mg/kg	1	Q6W		

Subsequent-line therapy if disease progression

Regorafenib (Child-Pugh Class A only [category 1])

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Regorafenib	160mg PO QD	1-21	Q4W		3

Nivolumab (Child-Pugh Class A or B7 only)

藥品名	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q2W		4

Ramucirumab (AFP ≥ 400mg/mL only [category 1])

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Ramucirumab	8 mg/kg	1	Q2W		6

Pembrolizumab (Child-Pugh Class A [category 2B])

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	up to 35	7

Lenvatinib (Child-Pugh Class A only)

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Lenvatinib	8 or 12* mg/day PO				5

Nivolumab + Ipilimumab (Child-Pugh Class A only) *

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	1 mg/kg	1	Q3W	4	10
Ipilimumab	3 mg/kg	1	Q3W	4	

Sorafenib (Child-Pugh Class A or B7)

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Sorafenib	400mg PO BID				11

Nivolumab + Ipilimumab (for TMB-H tumors)

藥品名 *	劑量 mg/m ²	給藥日	頻率	週期	參考文獻
Nivolumab	240 mg	1	Q2W		15
Ipilimumab	1 mg/kg	1	Q6W		

*三院有個別版本

參考文獻

1. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med 2008;359(4):378-390.
2. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
3. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
4. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-2502.

5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018;391:1163-1173.
6. Zhu AX, Kang YK, Yen CJ, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. *J Clin Oncol* 2018;36:4003.
7. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. *Lancet Oncol.* 2018 Jul;19(7):940-952.
8. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med* 2020;382:1894-1905.
9. Yau T, Park JW, Finn RS, et al. CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma. *Ann Oncol* 2019 Oct;30 Suppl 5:v874-v87.
10. Yau T, Kang Y, Kim T, et al. Nivolumab + ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: Results from CheckMate 040. *J Clin Oncol* 2019;37:4012-4012.
11. Tomonari T, Sato Y, Tanaka H, Tanaka T, et al. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. *JGH Open* 2020;4:1135-1139.
12. Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [abstract]. *J Clin Oncol* 2022;40:Abstract 379.
13. van Laethem JL, Borbath I, Karwal M, et al. Updated results for pembrolizumab (pembro) monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC) in the phase II KEYNOTE-224 study [abstract]. *Ann Oncol* 2021;32:Abstract 933P.
14. D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. *Hepatology* 2022;76:1000-1012.

15. Schenker M, Burotto M, Richardet M, et al. CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden [abstract]. Cancer Res 2022;82:Abstract CT022.